ClinicalTrials.gov
public full text
Public Domain
Ocrelizumab VErsus Rituximab Off-Label at the Onset of Relapsing MS Disease
This is a multicenter non-inferiority study, designed to establish non-inferiority of the study treatment rituximab compared with the comparator ocrelizumab for consecutively included patients (male or female) with active relapsing-remitting multiple sclerosis aged 18-60 years.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Randomized Placebo-Controlled, Crossover-Design Study of the Effects of Low Dose Naltrexone#1087448
- Ocrevus Zunovo for MS: Mixed Methods#898098
- Quantifying MS Progression in the Era of Highly Effective Therapy: Trial Design Implications#261200
- Optimizing IFN Beta - 1B Dose#1046151
- A Study to Investigate Effects of Ocrelizumab Treatment on Neurofilament Light Chain (NfL) Levels and Participant Satisfaction in Participants With Multiple Sclerosis (MS)#966242
Record · ID 877855
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive